

Jukka Westermarck

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1186507/jukka-westermarck-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

7,452
citations

38
h-index

86
g-index

112
ext. papers

8,405
ext. citations

8.4
avg, IF

5.95
L-index

#	Paper	IF	Citations
99	Chk1 Inhibition Ameliorates Alzheimer β Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	2
98	Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.. <i>Oral Oncology</i> , 2022 , 127, 105772	4.4	0
97	Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. <i>Clinical Cancer Research</i> , 2021 , 27, 2848-2860	12.9	5
96	Druggable cancer phosphatases. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	15
95	Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions. <i>Cancers</i> , 2021 , 13,	6.6	2
94	CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. <i>Cancer Research</i> , 2021 , 81, 4319-4331	10.1	4
93	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. <i>Cell</i> , 2021 , 184, 3143-3162.e32	56.2	20
92	Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2021 , 21, 868	4.8	1
91	Cancer stem cell phosphatases. <i>Biochemical Journal</i> , 2021 , 478, 2899-2920	3.8	1
90	Piecing Together a Broken Tumor Suppressor Phosphatase for Cancer Therapy. <i>Cell</i> , 2020 , 181, 514-517	56.2	11
89	Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. <i>Journal of Biological Chemistry</i> , 2020 , 295, 4194-4211	5.4	19
88	Is Coamplified with in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis. <i>Cancer Research</i> , 2020 , 80, 1414-1427	10.1	12
87	Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer β Disease Pathogenesis in Cell and Animal Models. <i>Neurotherapeutics</i> , 2020 , 17, 1087-1103	6.4	10
86	CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling. <i>IScience</i> , 2020 , 23, 100947	6.1	7
85	Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells. <i>Current Research in Immunology</i> , 2020 , 1, 10-22	1	3
84	Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. <i>Brain Communications</i> , 2020 , 2, fcaa002	4.5	7
83	(2S, 4R)-4-[F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models. <i>Molecular Imaging and Biology</i> , 2020 , 22, 969-978	3.8	13

82	Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein. <i>Cancer Cell</i> , 2020 , 38, 20-22	24.3	3
81	Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. <i>Oncogene</i> , 2020 , 39, 703-717	9.2	16
80	Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6	8
79	Genistein Decreases APP/tau Phosphorylation and Ameliorates A β Overproduction Through Inhibiting CIP2A. <i>Current Alzheimer Research</i> , 2019 , 16, 732-740	3	4
78	CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits. <i>Neurobiology of Aging</i> , 2019 , 75, 198-208	5.6	10
77	Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. <i>International Journal of Cancer</i> , 2019 , 144, 1735-1745	7.5	33
76	Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2018 , 96, 157-164	5.6	50
75	Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer. <i>Cancer Medicine</i> , 2018 , 7, 698-706	4.8	11
74	Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back. <i>FEBS Journal</i> , 2018 , 285, 4139-4145	5.7	27
73	Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E7351-E7360	11.5	21
72	PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	72
71	CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease. <i>Cell Reports</i> , 2018 , 24, 713-723	10.6	39
70	Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. <i>EMBO Reports</i> , 2017 , 18, 437-450	6.5	61
69	PP2A Inactivation Mediated by Haploinsufficiency Promotes Cancer Development. <i>Cancer Research</i> , 2017 , 77, 6825-6837	10.1	24
68	PWP1 Mediates Nutrient-Dependent Growth Control through Nucleolar Regulation of Ribosomal Gene Expression. <i>Developmental Cell</i> , 2017 , 43, 240-252.e5	10.2	12
67	Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. <i>Nature Communications</i> , 2016 , 7, 12237	17.4	71
66	Optimized design and analysis of preclinical intervention studies in vivo. <i>Scientific Reports</i> , 2016 , 6, 30723	23.9	28
65	CIP2A Promotes T-Cell Activation and Immune Response to <i>Listeria monocytogenes</i> Infection. <i>PLoS ONE</i> , 2016 , 11, e0152996	3.7	12

64	MYC is not detected in highly proliferating normal spermatogonia but is coupled with CIP2A in testicular cancers. <i>Matters</i> , 2016 , 2016,	0	1
63	Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity. <i>Blood</i> , 2016 , 128, 2909-2909	2.2	1
62	Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery. <i>International Journal of Nanomedicine</i> , 2016 , 11, 6591-6608	7.3	38
61	Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2016 , 45, 329-37	3.3	5
60	Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1. <i>Biochemical Society Transactions</i> , 2016 , 44, 1683-1693	5.1	33
59	PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. <i>Cancer Research</i> , 2016 , 76, 7001-7011	7.1	30
58	Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 69-81	5	6
57	Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation. <i>Cell Reports</i> , 2015 , 12, 1019-31	10.6	37
56	Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer. <i>Cancer Medicine</i> , 2015 , 4, 1798-808	4.8	12
55	Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. <i>Scientific Reports</i> , 2015 , 5, 13099	4.9	38
54	Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data. <i>Molecular and Cellular Proteomics</i> , 2015 , 14, 3274-83	7.6	12
53	CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. <i>Oncotarget</i> , 2015 , 6, 144-58	3.3	37
52	CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. <i>Oncotarget</i> , 2015 , 6, 19661-70	3.3	21
51	Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. <i>Clinical Cancer Research</i> , 2014 , 20, 3644-50	12.9	26
50	Mesoporous silica nanoparticles with redox-responsive surface linkers for charge-reversible loading and release of short oligonucleotides. <i>Dalton Transactions</i> , 2014 , 43, 4115-26	4.3	65
49	KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo. <i>Cell Cycle</i> , 2014 , 13, 3670-84	4.7	12
48	ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. <i>PLoS ONE</i> , 2014 , 9, e92444	3.7	317
47	Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. <i>Cancer Research</i> , 2013 , 73, 6757-69	10.1	35

46	Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. <i>Cancer Discovery</i> , 2013 , 3, 182-97	24.4	90
45	Identification of protein interactions involved in cellular signaling. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 1752-63	7.6	60
44	Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. <i>Cancer Research</i> , 2013 , 73, 6548-53	10.1	117
43	CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. <i>PLoS ONE</i> , 2012 , 7, e33209	3.7	43
42	Identification and regulation of a stage-specific stem cell niche enriched by Nanog-positive spermatogonial stem cells in the mouse testis. <i>Stem Cells</i> , 2012 , 30, 1008-20	5.8	24
41	Nucleolar AATF regulates c-Jun-mediated apoptosis. <i>Molecular Biology of the Cell</i> , 2012 , 23, 4323-32	3.5	20
40	ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. <i>PLoS ONE</i> , 2011 , 6, e17979	3.7	49
39	Hypoxia-activated Smad3-specific dephosphorylation by PP2A. <i>Journal of Biological Chemistry</i> , 2010 , 285, 3740-3749	5.4	44
38	Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc, and c-Jun. <i>Methods in Molecular Biology</i> , 2010 , 647, 31-6	1.4	23
37	CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. <i>Differentiation</i> , 2010 , 80, 68-77	3.5	27
36	Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. <i>Genome Medicine</i> , 2010 , 2, 65	14.4	133
35	MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 793-805	9.7	157
34	PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. <i>Cancer Research</i> , 2009 , 69, 2870-7	10.1	65
33	CIP2A is associated with human breast cancer aggressivity. <i>Clinical Cancer Research</i> , 2009 , 15, 5092-100	12.9	190
32	Integrated network analysis platform for protein-protein interactions. <i>Nature Methods</i> , 2009 , 6, 75-7	21.6	231
31	PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation. <i>Blood</i> , 2009 , 113, 1268-77	2.2	22
30	Identification of nucleolar effects in JNK-deficient cells. <i>FEBS Letters</i> , 2008 , 582, 3145-51	3.8	7
29	Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. <i>FASEB Journal</i> , 2008 , 22, 954-65	0.9	635

28	Multiple pathways regulated by the tumor suppressor PP2A in transformation. <i>Trends in Molecular Medicine</i> , 2008 , 14, 152-60	11.5	276
27	Mechanisms of MYC stabilization in human malignancies. <i>Cell Cycle</i> , 2008 , 7, 592-6	4.7	115
26	c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21. <i>Journal of Biological Chemistry</i> , 2008 , 283, 7046-53	5.4	36
25	IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration. <i>Journal of Cell Science</i> , 2008 , 121, 854-64	5.3	80
24	CIP2A inhibits PP2A in human malignancies. <i>Cell</i> , 2007 , 130, 51-62	56.2	591
23	Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists. <i>Cancer Research</i> , 2006 , 66, 11817-24	10.1	32
22	Single-step Strep-tag purification for the isolation and identification of protein complexes from mammalian cells. <i>Proteomics</i> , 2005 , 5, 1199-203	4.8	96
21	DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. <i>Molecular and Cellular Biology</i> , 2005 , 25, 5040-51	4.8	40
20	p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2. <i>Cancer Research</i> , 2003 , 63, 3473-7	10.1	66
19	The DEXD/H-box RNA helicase RHII/Gu is a co-factor for c-Jun-activated transcription. <i>EMBO Journal</i> , 2002 , 21, 451-60	13	87
18	p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. <i>Molecular and Cellular Biology</i> , 2001 , 21, 2373-83	4.8	170
17	Regulation of matrix metalloproteinase expression in tumor invasion. <i>FASEB Journal</i> , 1999 , 13, 781-792	0.9	1276
16	Integrin alpha2beta1 mediates isoform-specific activation of p38 and upregulation of collagen gene transcription by a mechanism involving the alpha2 cytoplasmic tail. <i>Journal of Cell Biology</i> , 1999 , 147, 401-16	7.3	190
15	Differential regulation of the AP-1 family members by UV irradiation in vitro and in vivo. <i>Cellular Signalling</i> , 1998 , 10, 191-5	4.9	36
14	Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase and p38. <i>Matrix Biology</i> , 1998 , 17, 547-57	11.4	77
13	Transcription of alpha2 integrin gene in osteosarcoma cells is enhanced by tumor promoters. <i>Experimental Cell Research</i> , 1998 , 243, 1-10	4.2	19
12	Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. <i>Journal of Biological Chemistry</i> , 1998 , 273, 5137-45	5.4	171
11	Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. <i>Oncogene</i> , 1997 , 14, 2651-60	9.2	128

10	Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. <i>Developmental Dynamics</i> , 1997 , 208, 387-97	2.9	225
9	Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. <i>FEBS Journal</i> , 1996 , 239, 239-47		152
8	TNF-R55-specific form of human tumor necrosis factor-alpha induces collagenase gene expression by human skin fibroblasts. <i>Journal of Investigative Dermatology</i> , 1995 , 105, 197-202	4.3	19
7	Differential regulation of decorin and biglycan gene expression by dexamethasone and retinoic acid in cultured human skin fibroblasts. <i>Journal of Investigative Dermatology</i> , 1995 , 104, 503-8	4.3	32
6	Integrin alpha 2 beta 1 is a positive regulator of collagenase (MMP-1) and collagen alpha 1(I) gene expression. <i>Journal of Biological Chemistry</i> , 1995 , 270, 13548-52	5.4	230
5	Rules for PP2A-controlled phosphosignalling and drug responses		3
4	Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma		1
3	Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias		1
2	A PP2A-Integrator complex fine-tunes transcription by opposing CDK9		1
1	PP2A inhibitor PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers		2